Anixa Biosciences delivered a non-revenue QQ3 2024 quarter characterized by a continued R&D-driven burn and a modest quarterly loss. On the top line, revenue remained nil, while gross profit registered a marginal negative of $3k, reflecting a cost structure dominated by development expenses rather than manufacturing or product sales. Total operating expenses were $3.592 million, with $1.925 million of research and development and $1.667 million of general and administrative outlays, implying a net loss of $3.277 million and an EBITDA of approximately -$3.589 million for the quarter. The company burned cash from operations by about $2.643 million, and while investing activities consumed $2.724 million, financing activities provided $0.149 million, resulting in a small net increase in cash during the quarter and a year-to-date liquidity profile that remains material for a pre-commercial biotech.
On the balance sheet, Anixa sits on a meaningful liquidity buffer: cash and short-term investments total roughly $20.745 million versus minimal near-term debt (long-term debt of $213k and short-term debt of $24k). The balance sheet shows a solid current ratio (11.31x) and a substantial stockholders’ equity base (~$21.77 million) despite a sizable accumulated deficit (retained earnings around -$237.9 million), reflecting a company with long cumulative losses but meaningful funding availability to advance its pipeline. The Q3 2024 earnings per share stood at -$0.10 on ~32.054 million diluted shares.
Management commentary in the period was focused on maintaining capital efficiency while advancing a diversified early-stage pipeline, including oncology vaccine concepts, immunotherapy approaches, and an antiviral program via a MolGenie collaboration. Given the lack of revenue and ongoing R&D emphasis, the near-term investment thesis hinges on milestone-driven value creation (data readouts, collaboration progress, and potential licensing opportunities) and the ability to sustain liquidity through external financing if required. Investors should monitor progress in preclinical/clinical milestones, collaboration outcomes, and any partner-driven inflection points that could de-risk the pipeline or unlock value.